<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="zap70-scid" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">zap70-scid</book-part-id>
      <title-group>
        <title><italic toggle="yes">ZAP70</italic>-Related Combined Immunodeficiency</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Walkovich</surname>
            <given-names>Kelly</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="zap70-scid.Tc.aff1"/>
          <email>kwalkovi@med.umich.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Vander Lugt</surname>
            <given-names>Mark</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="zap70-scid.Tc.aff1"/>
          <email>marvande@med.umich.edu</email>
        </contrib>
      </contrib-group>
      <aff id="zap70-scid.Tc.aff1">University of Michigan Medical School<break/>Ann Arbor, Michigan</aff>
      <pub-history>
        <date date-type="created">
          <day>20</day>
          <month>10</month>
          <year>2009</year>
        </date>
        <date date-type="updated">
          <day>8</day>
          <month>6</month>
          <year>2017</year>
        </date>
        <date date-type="revised">
          <day>6</day>
          <month>9</month>
          <year>2012</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="yci" document-type="chapter">Y Chromosome Infertility</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="app2" document-type="appendix">Appendix: Interpretation of Sequence Analysis Results</related-object>
      <abstract id="zap70-scid.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p><italic toggle="yes">ZAP70</italic>-related combined immunodeficiency (<italic toggle="yes">ZAP70</italic>-related CID) is a cell-mediated immunodeficiency caused by abnormal T-cell receptor (TCR) signaling. Affected children usually present in the first year of life with recurrent bacterial, viral, and opportunistic infections, diarrhea, and failure to thrive. Severe lower-respiratory infections and oral candidiasis are common. Affected children usually do not survive past their second year without hematopoietic stem cell transplantation (HSCT).</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of <italic toggle="yes">ZAP70</italic>-related CID is suggested by low to absent CD8<sup>+</sup> T cells in an individual with normal CD3+ and CD4+ T-cell counts. Additional supportive laboratory features include absent proliferation of CD4<sup>+</sup> T cells in response to mitogens and antigens, and absent ZAP-70 protein expression. The diagnosis is established in a proband by identification of biallelic pathogenic variants in <italic toggle="yes">ZAP70</italic> on molecular genetic testing.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Supportive care includes immediate intravenous immunoglobulin (IVIG) and antibacterial, antifungal, antiviral, and <italic toggle="yes">Pneumocystis</italic>
<italic toggle="yes">jiroveci</italic> prophylaxis to control and reduce the occurrence of infections.</p>
          <p><italic toggle="yes">Prevention of primary manifestations:</italic> Allogeneic HSCT to reconstitute the immune system, preferably prior to the onset of infections.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Use of irradiated, leukoreduced, cytomegalovirus (CMV)-safe blood products; deferment of immunizations until immune reconstitution; consideration for formula feeds in place of breast feeding until CMV status of mother is known.</p>
          <p><italic toggle="yes">Surveillance:</italic> Individuals with milder findings or those who have not undergone HSCT need to be monitored for worsening of immune function with periodic assessment of clinical status and functional lymphocyte responsiveness. Following a successful HSCT, the following should be routinely monitored: growth, psychomotor development, complete blood counts, liver and renal function, immune status, donor and recipient chimerism, development of post-transplant complications.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Non-irradiated blood products; live viral, live mycobacterial, and live bacterial vaccinations; contaminated water sources; exposure to fungus-enriched environments (e.g., construction sites, agricultural areas with active soil disruption, mulch, hay).</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> Because the outcome of HSCT in children with <italic toggle="yes">ZAP70</italic>-related CID is significantly improved by performing HSCT prior to the onset of severe infections, early testing of at-risk sibs should be considered. In addition, any sibs considered as bone marrow donors must be evaluated for <italic toggle="yes">ZAP70</italic>-related CID prior to donation.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p><italic toggle="yes">ZAP70</italic>-related CID is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being a carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk family members and prenatal diagnosis for pregnancies at increased risk are possible if the pathogenic variants in the family are known.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="zap70-scid.Diagnosis">
        <title>Diagnosis</title>
        <sec id="zap70-scid.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p><italic toggle="yes">ZAP70</italic>-related combined immunodeficiency (<italic toggle="yes">ZAP70</italic>-related CID) <bold>should be suspected</bold> in individuals who present with the following findings within the first two years of life:</p>
          <list list-type="bullet">
            <list-item>
              <p>Recurrent viral, bacterial, and opportunistic infections</p>
            </list-item>
            <list-item>
              <p>Chronic diarrhea and failure to thrive</p>
            </list-item>
            <list-item>
              <p>Characteristic results of lymphocyte subset analysis of CD3, CD4, and CD8 T cells, lymphocyte functional testing, and ZAP-70 protein expression (see <bold>Lymphocyte development and numbers</bold>)</p>
            </list-item>
          </list>
          <p>Note: Individuals with non-classic <italic toggle="yes">ZAP70</italic>-related CID may present at an older age with symptoms of autoimmunity, lymphoproliferation, and/or immune dysregulation with or without evidence of immunodeficiency.</p>
          <p><bold>Lymphocyte development and numbers.</bold> In <italic toggle="yes">ZAP70</italic>-related CID, total lymphocyte counts can range from normal to high.</p>
          <list list-type="bullet">
            <list-item>
              <p>Thymic architecture is largely preserved in individuals with <italic toggle="yes">ZAP70</italic>-related CID; however, compared to controls, a smaller medullary zone, decreased numbers of AIRE+ medullary thymic epithelial cells, and decreased numbers of dendritic cell numbers may be seen [<xref ref-type="bibr" rid="zap70-scid.REF.poliani.2013">Poliani et al 2013</xref>].</p>
            </list-item>
            <list-item>
              <p>T-cell counts:</p>
              <list list-type="bullet">
                <list-item>
                  <p>CD3<sup>+</sup> cell counts are typically normal.</p>
                </list-item>
                <list-item>
                  <p>CD4<sup>+</sup> cell counts are normal or elevated and may account for 60%-80% of the lymphocytes in individuals with <italic toggle="yes">ZAP70</italic>-related CID. Numbers of CD4+ recent thymic emigrants may be decreased [<xref ref-type="bibr" rid="zap70-scid.REF.hauck.2015.103">Hauck et al 2015</xref>].</p>
                </list-item>
                <list-item>
                  <p>CD8<sup>+</sup> cells are absent or extremely low, often comprising only 0%-2% of the child&#x02019;s total T-cell count in individuals with <italic toggle="yes">ZAP70</italic>-related CID [<xref ref-type="bibr" rid="zap70-scid.REF.arpaia.1994.947">Arpaia et al 1994</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.noraz.2000.15832">Noraz et al 2000</xref>].</p>
                </list-item>
                <list-item>
                  <p>Numbers of regulatory T cells may be normal or decreased [<xref ref-type="bibr" rid="zap70-scid.REF.poliani.2013">Poliani et al 2013</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.hauck.2015.103">Hauck et al 2015</xref>].</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>B cell counts and NK cell counts are normal.</p>
            </list-item>
          </list>
          <p><bold>Lymphocyte function.</bold> T-cell responses to stimuli that act through the T-cell receptor (TCR) are absent or severely diminished:</p>
          <list list-type="bullet">
            <list-item>
              <p>Absent or decreased proliferation to CD3 antibody [<xref ref-type="bibr" rid="zap70-scid.REF.roifman.2010.1226">Roifman et al 2010</xref>]</p>
            </list-item>
            <list-item>
              <p>Absent or decreased proliferation of CD4<sup>+</sup> cells in response to mitogens (e.g., PHA, ConA) [<xref ref-type="bibr" rid="zap70-scid.REF.roifman.2012.177">Roifman et al 2012</xref>]</p>
            </list-item>
            <list-item>
              <p>Intact proliferative response to mitogenic stimuli that bypass the TCR (e.g., PMA/Ionomycin) [<xref ref-type="bibr" rid="zap70-scid.REF.elder.1994.1596">Elder et al 1994</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.elder.1997.546">Elder 1997</xref>]</p>
            </list-item>
            <list-item>
              <p>Normal TCR V&#x003b2; repertoire in both CD4+ and CD8+ T cells [<xref ref-type="bibr" rid="zap70-scid.REF.roifman.2010.1226">Roifman et al 2010</xref>]</p>
            </list-item>
            <list-item>
              <p>In CD4 cells: limited differentiation into Th2 cells and resistance to Fas-induced cell death [<xref ref-type="bibr" rid="zap70-scid.REF.roifman.2010.1226">Roifman et al 2010</xref>]</p>
            </list-item>
            <list-item>
              <p>In regulatory T cells: potentially decreased expression of <italic toggle="yes">CTLA4</italic> and <italic toggle="yes">TGFB</italic> leading to increased risk of autoimmunity [<xref ref-type="bibr" rid="zap70-scid.REF.roifman.2010.1226">Roifman et al 2010</xref>]</p>
            </list-item>
          </list>
          <p><bold>ZAP-70 protein expression.</bold> Testing of CD4<sup>+</sup> T cells reveals absence or near absence of ZAP-70 protein in most affected individuals. Recent reports suggest that the amount of residual ZAP-70 protein expression influences the clinical phenotype [<xref ref-type="bibr" rid="zap70-scid.REF.picard.2009.1966">Picard et al 2009</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.chan.2016.155">Chan et al 2016</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.gavino.2017.1688">Gavino et al 2017</xref>]. Expression of Syk, a related tyrosine kinase important in T-cell signaling, may partially compensate for ZAP-70 signaling in some individuals [<xref ref-type="bibr" rid="zap70-scid.REF.toyabe.2001.164">Toyabe et al 2001</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.hauck.2015.103">Hauck et al 2015</xref>].</p>
          <p>
            <bold>Immunoglobulin concentrations and function</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Immunoglobulin levels vary by individual. Many affected individuals have severe hypogammaglobulinemia, but normal immunoglobulins or elevated IgA, IgM, and/or IgE can also be seen [<xref ref-type="bibr" rid="zap70-scid.REF.turul.2009.87">Turul et al 2009</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.cuvelier.2016.713">Cuvelier et al 2016</xref>].</p>
            </list-item>
            <list-item>
              <p>Although functional antibody responses to immunization are present in a few persons [<xref ref-type="bibr" rid="zap70-scid.REF.turul.2009.87">Turul et al 2009</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.hauck.2015.103">Hauck et al 2015</xref>], this finding does not indicate that all specific antigenic responses are intact.</p>
            </list-item>
          </list>
          <p><bold>Newborn screening.</bold> The utility of TREC screening for individuals with <italic toggle="yes">ZAP70</italic>-related CID continues to be controversial. Although some have shown that TREC levels in individuals with confirmed <italic toggle="yes">ZAP70</italic>-related CID are very low compared to age-matched controls [<xref ref-type="bibr" rid="zap70-scid.REF.roifman.2010.1226">Roifman et al 2010</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.roifman.2012.177">Roifman et al 2012</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.aluri.2016">Aluri et al 2016</xref>], others have shown that a substantial portion of individuals with <italic toggle="yes">ZAP70</italic>-related CID have TREC levels above the cutoffs used for newborn screening and could be missed [<xref ref-type="bibr" rid="zap70-scid.REF.grazioli.2014.209">Grazioli et al 2014</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.jilkina.2014.324">Jilkina et al 2014</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.hauck.2015.103">Hauck et al 2015</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.schroeder.2016.50">Schroeder et al 2016</xref>]. Therefore, newborn screening results must be interpreted with caution in individuals with clinical findings consistent with <italic toggle="yes">ZAP70</italic>-related CID or in populations with a high prevalence of <italic toggle="yes">ZAP70</italic>-related CID.</p>
        </sec>
        <sec id="zap70-scid.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of <italic toggle="yes">ZAP70</italic>-related CID <bold>is established</bold> in a proband by identification of biallelic pathogenic variants in <italic toggle="yes">ZAP70</italic> on molecular genetic testing (see <xref ref-type="table" rid="zap70-scid.T.molecular_genetic_testing_u">Table 1</xref>).</p>
          <p>Molecular genetic testing approaches can include <bold>single-gene testing</bold> or use of a <bold>multi-gene panel</bold>:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Single-gene testing.</bold> Sequence analysis of <italic toggle="yes">ZAP70</italic> is performed.</p>
              <p>Note: (1) No deletions or duplications of <italic toggle="yes">ZAP70</italic> have been reported. (2) Targeted analysis for the c.1624-11G&#x0003e;A variant can be performed first in individuals of Mennonite ancestry.</p>
            </list-item>
            <list-item>
              <p><bold>A multi-gene panel</bold> that includes <italic toggle="yes">ZAP70</italic> and other genes of interest (see <xref ref-type="sec" rid="zap70-scid.Differential_Diagnosis">Differential Diagnosis</xref>) may also be considered.</p>
              <p>Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene varies by laboratory and over time. (2) Some multi-gene panels may include genes not associated with the condition discussed in this <italic toggle="yes">GeneReview</italic>; thus, clinicians need to determine which multi-gene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of pathogenic variants in genes that do not account for the underlying phenotype. (3) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing based tests.</p>
              <p>For more information on multi-gene panels click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.MultiGene_Panels" object-type="sec">here</related-object>.</p>
            </list-item>
          </list>
          <table-wrap id="zap70-scid.T.molecular_genetic_testing_u" orientation="portrait" position="anchor">
            <label>Table 1. </label>
            <caption>
              <p>Molecular Genetic Testing Used in <italic toggle="yes">ZAP70</italic>-Related Combined Immunodeficiency</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_zap70-scid.T.molecular_genetic_testing_u_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_zap70-scid.T.molecular_genetic_testing_u_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                  <th id="hd_h_zap70-scid.T.molecular_genetic_testing_u_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands with Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_zap70-scid.T.molecular_genetic_testing_u_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">ZAP70</italic>
                  </td>
                  <td headers="hd_h_zap70-scid.T.molecular_genetic_testing_u_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_zap70-scid.T.molecular_genetic_testing_u_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">44/44&#x000a0;<sup>4</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_zap70-scid.T.molecular_genetic_testing_u_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>5</sup></td>
                  <td headers="hd_h_zap70-scid.T.molecular_genetic_testing_u_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Unknown&#x000a0;<sup>6</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="zap70-scid.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="zap70-scid" object-id="zap70-scid.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="zap70-scid.TF.1.2">
                <label>2. </label>
                <p>See <xref ref-type="sec" rid="zap70-scid.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
              </fn>
              <fn id="zap70-scid.TF.1.3">
                <label>3. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="zap70-scid.TF.1.4">
                <label>4. </label>
                <p><xref ref-type="bibr" rid="zap70-scid.REF.arpaia.1994.947">Arpaia et al [1994]</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.chan.1994.1599">Chan et al [1994]</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.elder.1994.1596">Elder et al [1994]</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.matsuda.1999.34515">Matsuda et al [1999]</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.meinl.2000.3578">Meinl et al [2000]</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.noraz.2000.15832">Noraz et al [2000]</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.barata.2001.413">Barata et al [2001]</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.elder.2001.656">Elder et al [2001]</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.toyabe.2001.164">Toyabe et al [2001]</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.fagioli.2003.133">Fagioli et al [2003]</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.picard.2009.1966">Picard et al [2009]</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.turul.2009.87">Turul et al [2009]</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.santos.2010.530">Santos et al [2010]</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.newell.2011.517">Newell et al [2011]</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.h_nig.2012.305">H&#x000f6;nig et al [2012]</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.roifman.2012.177">Roifman et al [2012]</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.karaca.2013.189">Karaca et al [2013]</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.kim.2013.1233">Kim et al [2013]</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.grazioli.2014.209">Grazioli et al [2014]</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.akar.2015.88">Akar et al [2015]</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.hauck.2015.103">Hauck et al [2015]</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.aluri.2016">Aluri et al [2016]</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.cuvelier.2016.713">Cuvelier et al [2016]</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.esenboga.2016.103">Esenboga et al [2016]</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.schroeder.2016.50">Schroeder et al [2016]</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.gavino.2017.1688">Gavino et al [2017]</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.shirkani.2017.70">Shirkani et al [2017]</xref></p>
              </fn>
              <fn id="zap70-scid.TF.1.5">
                <label>5. </label>
                <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
              </fn>
              <fn id="zap70-scid.TF.1.6">
                <label>6. </label>
                <p>No data on detection rate of gene-targeted deletion/duplication analysis are available.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
      </sec>
      <sec id="zap70-scid.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="zap70-scid.Clinical_Description">
          <title>Clinical Description</title>
          <p>Individuals with <italic toggle="yes">ZAP70</italic>-related CID characteristically present in the first two years of life with recurrent bacterial, viral (including live-virus vaccine strains), and opportunistic infections, diarrhea, and failure to thrive. Severe lower-respiratory infections are seen, most notably <italic toggle="yes">Pneumocystis jiroveci</italic> infections and viral infections. Oral candidiasis is also common [<xref ref-type="bibr" rid="zap70-scid.REF.cuvelier.2016.713">Cuvelier et al 2016</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.schroeder.2016.50">Schroeder et al 2016</xref>].</p>
          <p>Other presentations have also been reported:</p>
          <list list-type="bullet">
            <list-item>
              <p>Reports of milder phenotypes in sibs of children who had died from <italic toggle="yes">ZAP70</italic>-related CID include a child age five months with recurrent lower-respiratory disease but no severe infections [<xref ref-type="bibr" rid="zap70-scid.REF.turul.2009.87">Turul et al 2009</xref>] and a child with persistent dermatitis resistant to therapy [<xref ref-type="bibr" rid="zap70-scid.REF.katamura.1999.124">Katamura et al 1999</xref>].</p>
            </list-item>
            <list-item>
              <p>A child age nine years with a <italic toggle="yes">ZAP70</italic> hypomorphic intronic pathogenic variant had an attenuated clinical and immunologic phenotype [<xref ref-type="bibr" rid="zap70-scid.REF.picard.2009.1966">Picard et al 2009</xref>] (see <xref ref-type="sec" rid="zap70-scid.GenotypePhenotype_Correlation">Genotype-Phenotype Correlations</xref>).</p>
            </list-item>
            <list-item>
              <p>A child age 11 months with <italic toggle="yes">ZAP70</italic>-related CID presented with lymphoma [<xref ref-type="bibr" rid="zap70-scid.REF.newell.2011.517">Newell et al 2011</xref>].</p>
            </list-item>
            <list-item>
              <p>BCG-related complications including axillary lymphadenitis or disseminated mycobacterial disease following BCG vaccination may be presenting features [<xref ref-type="bibr" rid="zap70-scid.REF.santos.2010.530">Santos et al 2010</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.esenboga.2016.103">Esenboga et al 2016</xref>].</p>
            </list-item>
            <list-item>
              <p>Two individuals presented with recurrent infections and silent brain infarcts; one also had congenital nephrotic syndrome and autoimmune hemolytic anemia [<xref ref-type="bibr" rid="zap70-scid.REF.akar.2015.88">Akar et al 2015</xref>].</p>
            </list-item>
            <list-item>
              <p>An individual with isolated treatment-refractory immune thrombocytopenia (ITP) has been described [<xref ref-type="bibr" rid="zap70-scid.REF.cuvelier.2016.713">Cuvelier et al 2016</xref>].</p>
            </list-item>
            <list-item>
              <p>Two sibs had refractory autoimmune features including nephrotic syndrome/proteinuria, bullous pemphigoid, and colitis; one also developed autoantibodies to factor VIII caused by a hypomorphic and weakly activating <italic toggle="yes">ZAP70</italic> pathogenic variant [<xref ref-type="bibr" rid="zap70-scid.REF.chan.2016.155">Chan et al 2016</xref>].</p>
            </list-item>
            <list-item>
              <p>An adult with a history of infantile-onset colitis, recurrent respiratory-tract infections, mucocutaneous candidiasis, HSV stomatitis, VZV infection, EBV lymphoproliferative disorder, recurrent CMV viremia, polyomaviremia, and epidermodysplasia verruciformis-like lesions due to HHV-23 was recently reported. A novel pathogenic variant (<xref ref-type="table" rid="zap70-scid.T.zap70_pathogenic_variants_d">c.1272C&#x0003e;T</xref>) that leads to an altered splice site and low levels of wild-type ZAP-70 protein was identified in this individual [<xref ref-type="bibr" rid="zap70-scid.REF.gavino.2017.1688">Gavino et al 2017</xref>].</p>
            </list-item>
          </list>
          <p>The long-term prognosis of untreated <italic toggle="yes">ZAP70</italic>-related CID is death from infection. Affected children have a declining quality of life and usually do not survive past their second year without hematopoietic stem cell transplantation (HSCT).</p>
        </sec>
        <sec id="zap70-scid.GenotypePhenotype_Correlation">
          <title>Genotype-Phenotype Correlations</title>
          <p>There is very little genotype-phenotype correlation reported in <italic toggle="yes">ZAP70</italic>-related CID; however, the amount of residual ZAP-70 protein expressed may modulate the clinical phenotype, as suggested by the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>A child with a hypomorphic intronic pathogenic variant (<xref ref-type="table" rid="zap70-scid.T.zap70_pathogenic_variants_d">c.837+121G&#x0003e;A</xref> in intron 7) who had had chronic eczema from age two months and recurrent infections from age two years. The frequency of infections declined at age six following introduction of co-trimoxazole and IVIG prophylaxis. Of note, an older sib with a history of multiple infections had died at age one year [<xref ref-type="bibr" rid="zap70-scid.REF.picard.2009.1966">Picard et al 2009</xref>].</p>
            </list-item>
            <list-item>
              <p>Two sibs with refractory autoimmune features including nephrotic syndrome/proteinuria, bullous pemphigoid, and colitis. One sib also developed autoantibodies to factor VIII. These sibs had compound heterozygous <italic toggle="yes">ZAP70</italic> pathogenic variants including a hypomorphic variant (<xref ref-type="table" rid="zap70-scid.T.zap70_pathogenic_variants_d">c.574C&#x0003e;T</xref>) and a weakly activating variant (<xref ref-type="table" rid="zap70-scid.T.zap70_pathogenic_variants_d">c.1079G&#x0003e;C</xref>) [<xref ref-type="bibr" rid="zap70-scid.REF.chan.2016.155">Chan et al 2016</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="zap70-scid.Nomenclature">
          <title>Nomenclature</title>
          <p><italic toggle="yes">ZAP70</italic>-related combined immunodeficiency may also be referred to as zeta-associated protein 70 deficiency or immunodeficiency 48.</p>
        </sec>
        <sec id="zap70-scid.Prevalence">
          <title>Prevalence</title>
          <p><italic toggle="yes">ZAP70</italic>-related CID was first described in 1994 in three individuals of Mennonite descent [<xref ref-type="bibr" rid="zap70-scid.REF.arpaia.1994.947">Arpaia et al 1994</xref>]. Since that time, more than 50 affected individuals have been described in the literature [<xref ref-type="bibr" rid="zap70-scid.REF.arpaia.1994.947">Arpaia et al 1994</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.chan.1994.1599">Chan et al 1994</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.elder.1994.1596">Elder et al 1994</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.elder.1995.110">Elder et al 1995</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.gelfand.1995.1057">Gelfand et al 1995</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.katamura.1999.124">Katamura et al 1999</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.matsuda.1999.34515">Matsuda et al 1999</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.meinl.2000.3578">Meinl et al 2000</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.noraz.2000.15832">Noraz et al 2000</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.barata.2001.413">Barata et al 2001</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.elder.2001.656">Elder et al 2001</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.toyabe.2001.164">Toyabe et al 2001</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.fagioli.2003.133">Fagioli et al 2003</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.picard.2009.1966">Picard et al 2009</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.turul.2009.87">Turul et al 2009</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.santos.2010.530">Santos et al 2010</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.newell.2011.517">Newell et al 2011</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.h_nig.2012.305">H&#x000f6;nig et al 2012</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.roifman.2012.177">Roifman et al 2012</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.karaca.2013.189">Karaca et al 2013</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.kim.2013.1233">Kim et al 2013</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.grazioli.2014.209">Grazioli et al 2014</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.akar.2015.88">Akar et al 2015</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.hauck.2015.103">Hauck et al 2015</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.aluri.2016">Aluri et al 2016</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.cuvelier.2016.713">Cuvelier et al 2016</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.esenboga.2016.103">Esenboga et al 2016</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.schroeder.2016.50">Schroeder et al 2016</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.gavino.2017.1688">Gavino et al 2017</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.shirkani.2017.70">Shirkani et al 2017</xref>].</p>
          <p>The prevalence of <italic toggle="yes">ZAP70</italic>-related CID is unknown but much lower than that of all forms of SCID, which is estimated at 1:50,000. Prevalence is higher in the Canadian Mennonite population, where a <xref ref-type="table" rid="zap70-scid.T.zap70_pathogenic_variants_d">c.1624-11G&#x0003e;A</xref> pathogenic variant resulting in destabilization of the ZAP-70 protein is frequently seen [<xref ref-type="bibr" rid="zap70-scid.REF.arpaia.1994.947">Arpaia et al 1994</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.jilkina.2014.324">Jilkina et al 2014</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.cuvelier.2016.713">Cuvelier et al 2016</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.schroeder.2016.50">Schroeder et al 2016</xref>].</p>
        </sec>
      </sec>
      <sec id="zap70-scid.Genetically_Related_Allelic_D">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with pathogenic variants in <italic toggle="yes">ZAP70</italic>.</p>
      </sec>
      <sec id="zap70-scid.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p><bold>Human immunodeficiency virus infection.</bold> Infants positive for human immunodeficiency virus (HIV+) may present with recurring infections and failure to thrive similar to CID. Individuals with HIV have CD4<sup>+</sup> lymphopenia, in contrast to the CD8<sup>+</sup> lymphopenia in individuals with <italic toggle="yes">ZAP70</italic>-related CID. In a neonate, the definitive diagnosis of HIV should be made by detection of cell-associated human immunodeficiency proviral DNA by polymerase chain reaction (PCR) amplification. See <xref ref-type="table" rid="zap70-scid.T.combined_immunodeficiencies">Table 2</xref> for additional considerations.</p>
        <table-wrap id="zap70-scid.T.combined_immunodeficiencies" orientation="portrait" position="anchor">
          <label>Table 2. </label>
          <caption>
            <p>Combined Immunodeficiencies in the Differential Diagnosis of <italic toggle="yes">ZAP70</italic>-Related CID</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_1_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_1_1">Disease Name</th>
                <th id="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_1_2" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_1_2">Gene Involved</th>
                <th id="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_1_3" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_1_3">Mode of<break/>Inheritance</th>
                <th id="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_1_4" valign="middle" colspan="4" align="left" scope="colgroup" rowspan="1">Lymphocyte Phenotype</th>
              </tr>
              <tr>
                <th headers="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_1_4" id="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">T</th>
                <th headers="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_1_4" id="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">B</th>
                <th headers="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_1_4" id="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_2_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">NK</th>
                <th headers="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_1_4" id="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_2_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Other</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><italic toggle="yes">ZAP70</italic>-related CID</td>
                <td headers="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">ZAP70</italic>
                </td>
                <td headers="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                <td headers="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_1_4 hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">+</td>
                <td headers="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_1_4 hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">+</td>
                <td headers="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_1_4 hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1">+</td>
                <td headers="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_1_4 hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_2_4" valign="middle" align="left" rowspan="1" colspan="1">CD4<sup>+</sup>/CD8<sup>-</sup></td>
              </tr>
              <tr>
                <td headers="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Familial CD8 deficiency</td>
                <td headers="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">CD8A</italic>
                </td>
                <td headers="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                <td headers="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_1_4 hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">+</td>
                <td headers="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_1_4 hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">+</td>
                <td headers="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_1_4 hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1">+</td>
                <td headers="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_1_4 hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_2_4" valign="middle" align="left" rowspan="1" colspan="1">CD4<sup>+</sup>/CD8<sup>&#x02013;</sup></td>
              </tr>
              <tr>
                <td headers="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">CD25 deficiency</td>
                <td headers="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">IL2RA</italic>
                </td>
                <td headers="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                <td headers="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_1_4 hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">+</td>
                <td headers="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_1_4 hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">+</td>
                <td headers="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_1_4 hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1">+</td>
                <td headers="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_1_4 hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_2_4" valign="middle" align="left" rowspan="1" colspan="1">CD4<sup>&#x02013;</sup>/CD8<sup>+</sup></td>
              </tr>
              <tr>
                <td headers="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">MHC II deficiency (BLS)</td>
                <td headers="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">See <bold>Major histocompatibility complex class II deficiency</bold></td>
                <td headers="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                <td headers="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_1_4 hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">+</td>
                <td headers="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_1_4 hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">+</td>
                <td headers="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_1_4 hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1">+</td>
                <td headers="hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_1_4 hd_h_zap70-scid.T.combined_immunodeficiencies_1_1_2_4" valign="middle" align="left" rowspan="1" colspan="1">CD4<sup>&#x02013;</sup>/CD8<sup>+</sup></td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>MHC II = major histocompatibility complex class II</p>
            </fn>
            <fn>
              <p>BLS = bare lymphocyte syndrome</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Familial CD8 deficiency</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/608957">608957</ext-link>) may have a presentation similar to <italic toggle="yes">ZAP70</italic>-related CID; the diagnosis can be confirmed with <italic toggle="yes">CD8A</italic> molecular genetic testing. The two individuals reported with this disease had recurring infections from early childhood and lived past their twenties [<xref ref-type="bibr" rid="zap70-scid.REF.de_la_callemartin.2001.117">de la Calle-Martin et al 2001</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.mancebo.2008.479">Mancebo et al 2008</xref>].</p>
        <p><bold>CD25 deficiency</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/606367">606367</ext-link>) also presents with recurring infections early in life with low to normal T-cell counts. However, the T cells are CD4<sup>&#x02013;</sup>/CD8<sup>+</sup>. The diagnosis can be confirmed with molecular genetic testing of <italic toggle="yes">IL2RA</italic> (<italic toggle="yes">CD25</italic>), which encodes the interleukin-2 receptor alpha chain.</p>
        <p><bold>Major histocompatibility complex (MHC) class II deficiency</bold> (also known as bare lymphocyte syndrome) (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/209920">209920</ext-link>) may have normal or elevated T-cell counts; however, the T cells are CD4<sup>&#x02013;</sup>/CD8<sup>+</sup>. As in other forms of CID, pathologic findings manifest within the first year of life. Major histocompatibility complex II expression is decreased. Molecular genetic testing may reveal pathogenic variants in <italic toggle="yes">RFX5</italic>, <italic toggle="yes">RFXAP</italic>, <italic toggle="yes">CIITA</italic>, or <italic toggle="yes">RFXANK</italic>, the four genes in which pathogenic variants are known to cause this disorder.</p>
        <p><xref ref-type="table" rid="zap70-scid.T.tcellnegative_forms_of_cid">Table 3</xref> differentiates several forms of combined immunodeficiency. Since CID presents as a phenotypically heterogeneous class of diseases, it is useful to recognize forms that present with low to normal T-cell counts. Lymphocyte subset testing and molecular genetic testing can implicate or rule out these other forms of CID.</p>
        <table-wrap id="zap70-scid.T.tcellnegative_forms_of_cid" orientation="portrait" position="anchor">
          <label>Table 3. </label>
          <caption>
            <p>T-Cell-Negative Forms of CID in the Differential Diagnosis of <italic toggle="yes">ZAP70</italic>-Related CID</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_1">Disease Name</th>
                <th id="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_2" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_2">Gene(s) Involved</th>
                <th id="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_3" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_3">Mode of<break/>Inheritance</th>
                <th id="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_4" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_4">Defect</th>
                <th id="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_5" valign="middle" colspan="3" align="left" scope="colgroup" rowspan="1">Lymphocyte Phenotype</th>
              </tr>
              <tr>
                <th headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_5" id="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">T</th>
                <th headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_5" id="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">B</th>
                <th headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_5" id="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_2_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">NK</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><italic toggle="yes">ZAP70</italic>-related CID</td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">ZAP70</italic>
                </td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_4" rowspan="4" valign="middle" align="left" colspan="1">Decreased protein expression</td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_5 hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">+</td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_5 hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">+</td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_5 hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1">+</td>
              </tr>
              <tr>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><italic toggle="yes">JAK3</italic>-related SCID (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/600802">600802</ext-link>)</td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">JAK3</italic>
                </td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_5 hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_2_1" valign="middle" colspan="1" align="left" rowspan="1">&#x02013;</td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_5 hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">+</td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_5 hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1">&#x02013;</td>
              </tr>
              <tr>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><italic toggle="yes">IL7R</italic>-related SCID (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/608971">608971</ext-link>)</td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">IL7R</italic>
                </td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_5 hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_2_1" valign="middle" colspan="1" align="left" rowspan="1">&#x02013;</td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_5 hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">+</td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_5 hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1">+</td>
              </tr>
              <tr>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">CD45 deficiency (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://omim.org/entry/608971">608971</ext-link>)</td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">PTPRC</italic>
                </td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_5 hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_2_1" valign="middle" colspan="1" align="left" rowspan="1">&#x02013;</td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_5 hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">+</td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_5 hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1">&#x02013;</td>
              </tr>
              <tr>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="ada" document-type="chapter">ADA deficiency</related-object>
                </td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">ADA</italic>
                </td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_4" rowspan="3" valign="middle" align="left" colspan="1">Decreased protein production</td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_5 hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">&#x02013;</td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_5 hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">&#x02013;</td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_5 hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1">&#x02013;</td>
              </tr>
              <tr>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">RAG1/2 deficiency (OMIIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://omim.org/entry/601457">601457</ext-link>)</td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"><italic toggle="yes">RAG1</italic>, <italic toggle="yes">RAG2</italic></td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_5 hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_2_1" valign="middle" colspan="1" align="left" rowspan="1">&#x02013;</td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_5 hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">&#x02013;</td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_5 hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1">+</td>
              </tr>
              <tr>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">SCID Athabascan (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://omim.org/entry/602450">602450</ext-link>)</td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">DCLRE1C</italic>
                </td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_5 hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_2_1" valign="middle" colspan="1" align="left" rowspan="1">&#x02013;</td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_5 hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">&#x02013;</td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_5 hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1">+</td>
              </tr>
              <tr>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="x-scid" document-type="chapter">X-linked SCID</related-object>
                </td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">IL2RG</italic>
                </td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">XL</td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Dysfunctional receptor</td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_5 hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">&#x02013;</td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_5 hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">+</td>
                <td headers="hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_1_5 hd_h_zap70-scid.T.tcellnegative_forms_of_cid_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1">&#x02013;</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p><bold>Omenn syndrome</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/603554">603554</ext-link>). Some individuals with <italic toggle="yes">ZAP70</italic>-related CID can present with Omenn syndrome-like features including rash, lymphadenopathy, hepatosplenomegaly, and eosinophilia.</p>
      </sec>
      <sec id="zap70-scid.Management">
        <title>Management</title>
        <sec id="zap70-scid.Evaluations_Following_Initial">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>The care of individuals diagnosed with <italic toggle="yes">ZAP70</italic>-related CID is best managed with a multidisciplinary team of providers including hematology/oncology/bone marrow transplantation, immunology, genetics, and infectious disease specialists. To establish the extent of disease and needs in an individual diagnosed with <italic toggle="yes">ZAP70</italic>-related combined immunodeficiency (CID), the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Assessment of growth</p>
            </list-item>
            <list-item>
              <p>Evaluation for common and opportunistic viral, bacterial, and fungal disease-causing agents</p>
            </list-item>
            <list-item>
              <p>Complete metabolic panel (liver and renal function), complete blood count (CBC) with differential and platelet count, lymphocyte subsets and mitogen proliferation, and quantitative immunoglobulins</p>
            </list-item>
            <list-item>
              <p>Consultation with a clinical geneticist and/or genetic counselor</p>
            </list-item>
            <list-item>
              <p>Consultation with a clinical immunologist</p>
            </list-item>
            <list-item>
              <p>Consultation for hematopoietic stem cell transplantation</p>
            </list-item>
          </list>
        </sec>
        <sec id="zap70-scid.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Treatment relies on prompt reconstitution of the individual&#x02019;s immune system (see <xref ref-type="sec" rid="zap70-scid.Prevention_of_Primary_Manifes">Prevention of Primary Manifestations</xref>).</p>
          <p>Supportive treatment includes IVIG and antibacterial, antifungal, antiviral, and <italic toggle="yes">Pneumocystis jiroveci</italic> prophylaxis to control and reduce the occurrence of infections.</p>
        </sec>
        <sec id="zap70-scid.Prevention_of_Primary_Manifes">
          <title>Prevention of Primary Manifestations</title>
          <p>The only curative therapy for <italic toggle="yes">ZAP70</italic>-related CID is allogeneic hematopoietic stem cell transplantation (HSCT). Extrapolated data show that the outcome of HSCT in children with SCID is significantly improved by performing HSCT prior to the onset of infections [<xref ref-type="bibr" rid="zap70-scid.REF.pai.2014.434">Pai et al 2014</xref>]. Children with <italic toggle="yes">ZAP70</italic>-related CID have been successfully transplanted using a variety of donors including haploidentical donors and unrelated umbilical cord blood [<xref ref-type="bibr" rid="zap70-scid.REF.noraz.2000.15832">Noraz et al 2000</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.elder.2001.656">Elder et al 2001</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.h_nig.2012.305">H&#x000f6;nig et al 2012</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.cuvelier.2016.713">Cuvelier et al 2016</xref>].</p>
          <list list-type="bullet">
            <list-item>
              <p>Outcomes are the best with HLA-matched, related donors.</p>
            </list-item>
            <list-item>
              <p>If an HLA-matched, related donor is not available, alternatives include:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Matched unrelated donor;</p>
                </list-item>
                <list-item>
                  <p>Umbilical cord blood donor;</p>
                </list-item>
                <list-item>
                  <p>Haploidentical parental bone marrow or mobilized peripheral blood stem cells that have been T-cell depleted.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>In contrast to individuals with SCID, individuals with <italic toggle="yes">ZAP70</italic>-related CID are typically treated with a chemotherapeutic conditioning regimen prior to HSCT, although some individuals have received unconditioned transplants with variable success, suggesting that conditioning may not be essential in some circumstances [<xref ref-type="bibr" rid="zap70-scid.REF.h_nig.2012.305">H&#x000f6;nig et al 2012</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.kim.2013.1233">Kim et al 2013</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.cuvelier.2016.713">Cuvelier et al 2016</xref>].</p>
            </list-item>
            <list-item>
              <p>The largest series of eight individuals with <italic toggle="yes">ZAP70</italic>-related CID who received HSCT using a variety of stem cell sources showed the following:</p>
              <list list-type="bullet">
                <list-item>
                  <p>All individuals were alive at a median of 13.5 years of follow up.</p>
                </list-item>
                <list-item>
                  <p>Two-thirds of the individuals who did not receive conditioning failed to have myeloid engraftment but have maintained stable mixed chimerism. In addition, three individuals who received stem cells from a matched sib did not receive conditioning prior to transplant and achieved engraftment.</p>
                </list-item>
                <list-item>
                  <p>75% of individuals developed acute graft-versus-host disease (GVHD) and 50% developed chronic GVHD.</p>
                </list-item>
                <list-item>
                  <p>Seven of eight individuals achieved freedom from IVIG and show evidence of class switching with resolution of dysregulated immunoglobulin production and six of the eight show evidence of antibody production to both protein and polysaccharide vaccines.</p>
                </list-item>
                <list-item>
                  <p>Two individuals receiving myeloablative conditioning have developed premature ovarian failure.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Cellular reconstitution following HSCT takes up to one year, while restoration of humoral immunity can take significantly longer, and may not occur in some individuals.</p>
            </list-item>
            <list-item>
              <p>Complications from HSCT include graft-versus-host disease, failure to reconstitute the humoral immune compartment, graft failure over time, and post-transplant lymphoproliferative disease [<xref ref-type="bibr" rid="zap70-scid.REF.skodasmith.2001.329">Skoda-Smith et al 2001</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.dvorak.2008.119">Dvorak &#x00026; Cowan 2008</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.pai.2014.434">Pai et al 2014</xref>].</p>
            </list-item>
            <list-item>
              <p>Affected individuals with poor humoral reconstitution are maintained on long-term immunoglobulin replacement.</p>
            </list-item>
          </list>
          <p>Individuals who do not undergo HSCT require close monitoring for worsening of immune function manifested by increased susceptibility to severe or opportunistic infections (see also <xref ref-type="sec" rid="zap70-scid.Surveillance">Surveillance</xref>). If clinical status worsens, rapid transition to HSCT should be considered.</p>
        </sec>
        <sec id="zap70-scid.Prevention_of_Secondary_Compl">
          <title>Prevention of Secondary Complications</title>
          <p>The following are appropriate:</p>
          <list list-type="bullet">
            <list-item>
              <p>Use of irradiated, leukoreduced, cytomegalovirus (CMV)-safe blood products</p>
            </list-item>
            <list-item>
              <p>Delay of immunizations until immune reconstitution</p>
            </list-item>
            <list-item>
              <p>Consideration for formula feeds in place of breast feeding until CMV status of mother is known. Caution should be taken to assess the quality of the water source for the infant formula.</p>
            </list-item>
          </list>
        </sec>
        <sec id="zap70-scid.Surveillance">
          <title>Surveillance</title>
          <p>Following a successful HSCT, the following should be routinely monitored:</p>
          <list list-type="bullet">
            <list-item>
              <p>Growth</p>
            </list-item>
            <list-item>
              <p>Psychomotor development</p>
            </list-item>
            <list-item>
              <p>Complete blood counts</p>
            </list-item>
            <list-item>
              <p>Liver and renal function</p>
            </list-item>
            <list-item>
              <p>Immune status</p>
            </list-item>
            <list-item>
              <p>Donor and recipient chimerism</p>
            </list-item>
            <list-item>
              <p>Development of post-transplant complications, particularly chronic graft-versus-host disease, decreased bone density, pulmonary and cardiac function, and gonadal function</p>
            </list-item>
          </list>
          <p>Individuals with milder findings or those who have not undergone HSCT also need to be monitored for worsening of immune function with periodic assessment of clinical status and functional lymphocyte responsiveness.</p>
        </sec>
        <sec id="zap70-scid.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Individuals with <italic toggle="yes">ZAP70</italic>-related CID should avoid the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Non-irradiated blood products</p>
            </list-item>
            <list-item>
              <p>Live virus vaccinations</p>
            </list-item>
            <list-item>
              <p><italic toggle="yes">Mycobacterium bovis</italic> (BCG) vaccine against tuberculosis, <italic toggle="yes">Salmonella typhi</italic> (Ty21a) vaccine against typhoid fever, and <italic toggle="yes">Vibrio cholerae</italic> (CVD 103-HgR) vaccine against cholera, which may be part of the routine vaccination schedule in countries where these diseases are endemic</p>
            </list-item>
            <list-item>
              <p>Contaminated water sources</p>
            </list-item>
            <list-item>
              <p>Exposure to fungus-enriched environments (e.g., construction sites, agricultural areas with active soil disruption, mulch, hay)</p>
            </list-item>
          </list>
        </sec>
        <sec id="zap70-scid.Evaluation_of_Relatives_at_Ri">
          <title>Evaluation of Relatives at Risk</title>
          <p>Because the outcome of HSCT in children with <italic toggle="yes">ZAP70</italic>-related CID is significantly improved by performing HSCT prior to the onset of severe infections, early testing of at-risk sibs should be considered. In addition, any sibs considered as bone marrow donors must be evaluated for <italic toggle="yes">ZAP70</italic>-related CID prior to donation.</p>
          <list list-type="bullet">
            <list-item>
              <p>If the <italic toggle="yes">ZAP70</italic> pathogenic variants in the family are known, molecular genetic testing can be used to clarify the genetic status of at-risk sibs.</p>
            </list-item>
            <list-item>
              <p>If the pathogenic variants in the family are not known, CBC, quantitative immunoglobulins, and lymphocyte subsets and proliferation can be used to clarify the genetic status (immunologic status) of at-risk sibs.</p>
            </list-item>
          </list>
          <p>See <xref ref-type="sec" rid="zap70-scid.Related_Genetic_Counseling_Is">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="zap70-scid.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>Appropriately screened blood products should be available, if needed, during the course of the pregnancy and delivery.</p>
        </sec>
        <sec id="zap70-scid.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p><bold>Gene therapy.</bold> Gene therapy has not been performed in <italic toggle="yes">ZAP70</italic>-related CID. Experimental studies utilizing gene therapy have been conducted on murine models [<xref ref-type="bibr" rid="zap70-scid.REF.adjali.2005.2287">Adjali et al 2005</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.irla.2008.e2059">Irla et al 2008</xref>] as well as human cells in vitro [<xref ref-type="bibr" rid="zap70-scid.REF.steinberg.2000.1392">Steinberg et al 2000</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.kofler.2004.1416">Kofler et al 2004</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.gavino.2017.1688">Gavino et al 2017</xref>]. Nonviral transfer methods (e.g., electro-gene transfer) have also been used to correct ZAP-70 deficiency in a murine model [<xref ref-type="bibr" rid="zap70-scid.REF.irla.2008.e2059">Irla et al 2008</xref>].</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="zap70-scid.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="zap70-scid.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p><italic toggle="yes">ZAP70</italic>-related combined immunodeficiency (CID) is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="zap70-scid.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected child are obligate heterozygotes (i.e., carriers of one <italic toggle="yes">ZAP70</italic> pathogenic variant).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes usually do not have CID-like symptoms. Parents of probands who did not appear to have clinical symptoms had intermediate expression levels compared to healthy controls [<xref ref-type="bibr" rid="zap70-scid.REF.turul.2009.87">Turul et al 2009</xref>]. Further studies suggested a ZAP-70 protein level threshold effect, which may explain why parents with decreased <italic toggle="yes">ZAP70</italic> expression may have no clinical features [<xref ref-type="bibr" rid="zap70-scid.REF.cauwe.2014.377">Cauwe et al 2014</xref>].</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being a carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Even if the sibs of a proband are asymptomatic, molecular genetic testing to determine their genetic status should be considered for the purpose of early diagnosis and treatment of those who have inherited both pathogenic variants (see <xref ref-type="sec" rid="zap70-scid.Evaluation_of_Relatives_at_Ri">Evaluation of Relatives at Risk</xref>).</p>
            </list-item>
          </list>
          <p>
            <bold>Offspring of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The offspring of an individual with <italic toggle="yes">ZAP70</italic>-related CID will inherit one pathogenic variant from the proband.</p>
            </list-item>
            <list-item>
              <p>The genetic status of the offspring will depend on the genetic status of the reproductive partner of the proband.</p>
              <list list-type="bullet">
                <list-item>
                  <p>If the reproductive partner is not affected and not a carrier, all offspring will be carriers.</p>
                </list-item>
                <list-item>
                  <p>If the reproductive partner is a carrier of a <italic toggle="yes">ZAP70</italic> pathogenic variant, each child will have a 50% chance of being affected and a 50% chance of being a carrier.</p>
                </list-item>
                <list-item>
                  <p>If the reproductive partner is also affected, all offspring will be affected.</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p><bold>Other family members.</bold> A detailed family history that includes the ancestry and culture of the proband&#x02019;s family may reveal consanguinity and geographic and genetic isolation &#x02013; risk factors that increase the likelihood of autosomal recessive diseases in a family. Some of the grandparents of the proband are carriers of a <italic toggle="yes">ZAP70</italic> pathogenic variant; therefore, sibs of the proband&#x02019;s parents and their offspring are at risk of being carriers.</p>
        </sec>
        <sec id="zap70-scid.Carrier_Heterozygote_Detectio">
          <title>Carrier (Heterozygote) Detection</title>
          <p>Carrier testing for at-risk relatives requires prior identification of the <italic toggle="yes">ZAP70</italic> pathogenic variants in the family.</p>
        </sec>
        <sec id="zap70-scid.Related_Genetic_Counseling_Is">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="zap70-scid.Evaluation_of_Relatives_at_Ri">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="zap70-scid.Prenatal_Testing_and_Preimpla">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the <italic toggle="yes">ZAP70</italic> pathogenic variants have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis for <italic toggle="yes">ZAP70</italic>-related CID are possible.</p>
          <p>An affected fetus does not require any specific management prior to delivery. Following delivery, early evaluation for potential HSCT should be performed because of the known benefit of early HSCT (see <xref ref-type="sec" rid="zap70-scid.Evaluation_of_Relatives_at_Ri">Evaluation of Relatives at Risk</xref>).</p>
        </sec>
      </sec>
      <sec id="zap70-scid.Resources">
        <title>Resources</title>
      </sec>
      <sec id="zap70-scid.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">ZAP70</italic> spans 26.3 kb of genomic DNA. The gene consists of 14 exons comprising 2450 bp. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="zap70-scid" object-id="zap70-scid.molgen.TA">Table A</related-object>.</p>
        <p><bold>Pathogenic variants.</bold>
<italic toggle="yes">ZAP70</italic> pathogenic variants reside mostly in the kinase domain, although pathogenic variants that result in loss of transcription or are located in the N-terminal SH2 domain and result in rapid degradation of ZAP-70 protein have been reported [<xref ref-type="bibr" rid="zap70-scid.REF.matsuda.1999.34515">Matsuda et al 1999</xref>, <xref ref-type="bibr" rid="zap70-scid.REF.auyeung.2009.41">Au-Yeung et al 2009</xref>]. More than 20 pathogenic variants including single-nucleotide variants, splice defects, and intragenic deletions have been reported. A pathogenic variant in the arginine residue (p.Arg465Cys) of the DLAARN motif of the kinase domain has been described (see <bold>Abnormal gene product</bold>).</p>
        <table-wrap id="zap70-scid.T.zap70_pathogenic_variants_d" orientation="portrait" position="anchor">
          <label>Table 4. </label>
          <caption>
            <p><italic toggle="yes">ZAP70</italic> Pathogenic Variants Discussed in This <italic toggle="yes">GeneReview</italic></p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_zap70-scid.T.zap70_pathogenic_variants_d_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                <th id="hd_h_zap70-scid.T.zap70_pathogenic_variants_d_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                <th id="hd_h_zap70-scid.T.zap70_pathogenic_variants_d_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_zap70-scid.T.zap70_pathogenic_variants_d_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.239C&#x0003e;A<break/>(448C&#x0003e;A)</td>
                <td headers="hd_h_zap70-scid.T.zap70_pathogenic_variants_d_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Pro80Gln</td>
                <td headers="hd_h_zap70-scid.T.zap70_pathogenic_variants_d_1_1_1_3" rowspan="8" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nucleotide/46488942">NM_001079.3</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/31455611">NP_001070.2</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_zap70-scid.T.zap70_pathogenic_variants_d_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.574C&#x0003e;T</td>
                <td headers="hd_h_zap70-scid.T.zap70_pathogenic_variants_d_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg192Trp</td>
              </tr>
              <tr>
                <td headers="hd_h_zap70-scid.T.zap70_pathogenic_variants_d_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">c.837+121G&#x0003e;A<break/>(836+121G&#x0003e;A)</td>
                <td headers="hd_h_zap70-scid.T.zap70_pathogenic_variants_d_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td headers="hd_h_zap70-scid.T.zap70_pathogenic_variants_d_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1079G&#x0003e;C</td>
                <td headers="hd_h_zap70-scid.T.zap70_pathogenic_variants_d_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg360Pro</td>
              </tr>
              <tr>
                <td headers="hd_h_zap70-scid.T.zap70_pathogenic_variants_d_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1272C&#x0003e;T</td>
                <td headers="hd_h_zap70-scid.T.zap70_pathogenic_variants_d_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">See footnote 2</td>
              </tr>
              <tr>
                <td headers="hd_h_zap70-scid.T.zap70_pathogenic_variants_d_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1393C&#x0003e;T</td>
                <td headers="hd_h_zap70-scid.T.zap70_pathogenic_variants_d_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg465Cys</td>
              </tr>
              <tr>
                <td headers="hd_h_zap70-scid.T.zap70_pathogenic_variants_d_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">c.1624-11G&#x0003e;A</td>
                <td headers="hd_h_zap70-scid.T.zap70_pathogenic_variants_d_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td headers="hd_h_zap70-scid.T.zap70_pathogenic_variants_d_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1714A&#x0003e;T<break/>(1923A&#x0003e;T)</td>
                <td headers="hd_h_zap70-scid.T.zap70_pathogenic_variants_d_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Met572Leu</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. GeneReviews staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: GeneReviews follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
            <fn id="zap70-scid.TF.4.1">
              <label>1. </label>
              <p>Variant designation that does not conform to current naming conventions</p>
            </fn>
            <fn id="zap70-scid.TF.4.2">
              <label>2. </label>
              <p>The variant is predicted to be silent (p.Gly355=) but has been demonstrated to result in a splicing defect [<xref ref-type="bibr" rid="zap70-scid.REF.gavino.2017.1688">Gavino et al 2017</xref>].</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold>
<italic toggle="yes">ZAP70</italic> codes for a 619-amino acid enzyme, ZAP-70, that contains two SH2 domains and one kinase domain. This Syk-protein tyrosine kinase family member plays a role in T cell development and activation. ZAP-70 directly interacts with the T-cell receptor (TCR) complex and is phosphorylated at tyrosine residues upon TCR stimulation, functioning in the initial step of TCR-mediated signal transduction with Src family kinases.</p>
        <p><bold>Abnormal gene product.</bold> Most pathogenic variants affect the kinase domain of <italic toggle="yes">ZAP70</italic> and cause a lack of or severely decreased protein expression. Loss of ZAP-70 activity leads to lack of signaling through the T-cell receptor and subsequent defects in CD8+ cell development and in global T-cell function [<xref ref-type="bibr" rid="zap70-scid.REF.fischer.2010.107">Fischer et al 2010</xref>].</p>
        <p>The residual function seen in CD4 and CD8 cells in individuals lacking ZAP-70 may be related to increased expression of Syk in affected cells [<xref ref-type="bibr" rid="zap70-scid.REF.hauck.2015.103">Hauck et al 2015</xref>]. In ZAP-70-deficient CD4+ cells, TCR stimulation was able to induce antigen-specific IgE responses in B cells in part via increased expression of Syk [<xref ref-type="bibr" rid="zap70-scid.REF.toyabe.2001.164">Toyabe et al 2001</xref>].</p>
      </sec>
      <sec id="zap70-scid.References">
        <title>References</title>
        <sec id="zap70-scid.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="zap70-scid.Literature_Cited.reflist0">
            <ref id="zap70-scid.REF.adjali.2005.2287">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Adjali</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marodon</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steinberg</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mongellaz</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thomas-Vaslin</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jacquet</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klatzmann</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>In vivo correction of ZAP-70 immunodeficiency by intrathymic gene transfer.</article-title>
                <source>J Clin Invest.</source>
                <volume>115</volume>
                <fpage>2287</fpage>
                <lpage>95</lpage>
                <pub-id pub-id-type="pmid">16075064</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.akar.2015.88">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Akar</surname>
                    <given-names>HH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patiroglu</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Akyildiz</surname>
                    <given-names>BN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tekerek</surname>
                    <given-names>NU</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Do&#x0011f;an</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Do&#x0011f;anay</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Burg</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dusunsel</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2015</year>
                <article-title>Silent brain infarcts in two patients with zeta chain-associated protein 70 kDa (ZAP70) deficiency.</article-title>
                <source>Clin Immunol</source>
                <volume>158</volume>
                <fpage>88</fpage>
                <lpage>91</lpage>
                <pub-id pub-id-type="pmid">25805655</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.aluri.2016">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Aluri</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Italia</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gupta</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dalvi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bavdekar</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Madkaikar</surname>
                    <given-names>M.</given-names>
                  </name>
                </person-group>
                <article-title>Low T cell receptor excision circles (TRECs) in a case of ZAP 70 deficient severe combined immunodeficiency (SCID) with a novel mutation from India.</article-title>
                <source>Blood Cells Mol Dis.</source>
                <year>2016</year>
                <comment>Epub ahead of print</comment>
                <pub-id pub-id-type="pmid">27839984</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.arpaia.1994.947">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Arpaia</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shahar</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dadi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cohen</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roifman</surname>
                    <given-names>CM</given-names>
                  </name>
                </person-group>
                <year>1994</year>
                <article-title>Defective T cell receptor signaling and CD8+ thymic selection in humans lacking zap-70 kinase.</article-title>
                <source>Cell</source>
                <volume>76</volume>
                <fpage>947</fpage>
                <lpage>58</lpage>
                <pub-id pub-id-type="pmid">8124727</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.auyeung.2009.41">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Au-Yeung</surname>
                    <given-names>BB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deindl</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hsu</surname>
                    <given-names>LY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Palacios</surname>
                    <given-names>EH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levin</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuriyan</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weiss</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>The structure, regulation, and function of ZAP-70.</article-title>
                <source>Immunol Rev</source>
                <volume>228</volume>
                <fpage>41</fpage>
                <lpage>57</lpage>
                <pub-id pub-id-type="pmid">19290920</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.barata.2001.413">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Barata</surname>
                    <given-names>LT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henriques</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hivroz</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jouanguy</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paiva</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Freitas</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coimbra</surname>
                    <given-names>HB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fischer</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>da Mota</surname>
                    <given-names>HC</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <comment>[Primary immunodeficiency secondary to ZAP-70 deficiency]</comment>
                <source>Acta Med Port</source>
                <volume>14</volume>
                <fpage>413</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">11762183</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.cauwe.2014.377">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cauwe</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tian</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Franckaert</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pierson</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Staats</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schlenner</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liston</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2014</year>
                <article-title>A novel Zap70 mutation with reduced protein stability demonstrates the rate-limiting threshold for Zap70 in T-cell receptor signalling.</article-title>
                <source>Immunology</source>
                <volume>141</volume>
                <fpage>377</fpage>
                <lpage>87</lpage>
                <pub-id pub-id-type="pmid">24164480</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.chan.1994.1599">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chan</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kadlecek</surname>
                    <given-names>TA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elder</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Filipovich</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuo</surname>
                    <given-names>WL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iwashima</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parslow</surname>
                    <given-names>TG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weiss</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>1994</year>
                <article-title>ZAP-70 deficiency in an autosomal recessive form of severe combined immunodeficiency.</article-title>
                <source>Science</source>
                <volume>264</volume>
                <fpage>1599</fpage>
                <lpage>601</lpage>
                <pub-id pub-id-type="pmid">8202713</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.chan.2016.155">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chan</surname>
                    <given-names>AY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Punwani</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kadlecek</surname>
                    <given-names>TA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cowan</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olson</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mathes</surname>
                    <given-names>EF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sunderam</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fu</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Srinivasan</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuriyan</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brenner</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weiss</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Puck</surname>
                    <given-names>JM</given-names>
                  </name>
                </person-group>
                <year>2016</year>
                <article-title>A novel human autoimmune syndrome caused by combined hypomorphic and activating mutations in ZAP-70.</article-title>
                <source>J Exp Med</source>
                <volume>213</volume>
                <fpage>155</fpage>
                <lpage>65</lpage>
                <pub-id pub-id-type="pmid">26783323</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.cuvelier.2016.713">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cuvelier</surname>
                    <given-names>GD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rubin</surname>
                    <given-names>TS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wall</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schroeder</surname>
                    <given-names>ML</given-names>
                  </name>
                </person-group>
                <year>2016</year>
                <article-title>Long-term outcomes of hematopoietic stem cell transplantation for ZAP70 deficiency.</article-title>
                <source>J Clin Immunol</source>
                <volume>36</volume>
                <fpage>713</fpage>
                <lpage>24</lpage>
                <pub-id pub-id-type="pmid">27438785</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.de_la_callemartin.2001.117">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>de la Calle-Martin</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hernandez</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ordi</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Casamitjana</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arostegui</surname>
                    <given-names>JI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caragol</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrando</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Labrador</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodriguez-Sanchez</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Espanol</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Familial CD8 deficiency due to a mutation in the CD8 alpha gene.</article-title>
                <source>J Clin Invest</source>
                <volume>108</volume>
                <fpage>117</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">11435463</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.dvorak.2008.119">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dvorak</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cowan</surname>
                    <given-names>MJ</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Hematopoietic stem cell transplantation for primary immunodeficiency disease.</article-title>
                <source>Bone Marrow Transplant</source>
                <volume>41</volume>
                <fpage>119</fpage>
                <lpage>26</lpage>
                <pub-id pub-id-type="pmid">17968328</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.elder.1997.546">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Elder</surname>
                    <given-names>ME</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>SCID due to ZAP-70 deficiency.</article-title>
                <source>J Pediatr Hematol Oncol</source>
                <volume>19</volume>
                <fpage>546</fpage>
                <lpage>50</lpage>
                <pub-id pub-id-type="pmid">9407944</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.elder.1995.110">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Elder</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hope</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parslow</surname>
                    <given-names>TG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Umetsu</surname>
                    <given-names>DT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wara</surname>
                    <given-names>DW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cowan</surname>
                    <given-names>MJ</given-names>
                  </name>
                </person-group>
                <year>1995</year>
                <article-title>Severe combined immunodeficiency with absence of peripheral blood CD8+ T cells due to ZAP-70 deficiency.</article-title>
                <source>Cell Immunol</source>
                <volume>165</volume>
                <fpage>110</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">7671314</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.elder.1994.1596">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Elder</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clever</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chan</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hope</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weiss</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parslow</surname>
                    <given-names>TG</given-names>
                  </name>
                </person-group>
                <year>1994</year>
                <article-title>Human severe combined immunodeficiency due to a defect in ZAP-70, a T cell tyrosine kinase.</article-title>
                <source>Science</source>
                <volume>264</volume>
                <fpage>1596</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">8202712</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.elder.2001.656">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Elder</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Skoda-Smith</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kadlecek</surname>
                    <given-names>TA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wu</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weiss</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Distinct T cell developmental consequences in humans and mice expressing identical mutations in the DLAARN motif of ZAP-70.</article-title>
                <source>J Immunol</source>
                <volume>166</volume>
                <fpage>656</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">11123350</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.esenboga.2016.103">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Esenboga</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ayvaz</surname>
                    <given-names>DC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cetinkaya</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Burg</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tezcan</surname>
                    <given-names>I</given-names>
                  </name>
                </person-group>
                <year>2016</year>
                <article-title>An infant with ZAP-70 deficiency with disseminated mycobacterial disease.</article-title>
                <source>J Clin Immunol</source>
                <volume>36</volume>
                <fpage>103</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">26707786</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.fagioli.2003.133">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fagioli</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Biasin</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berger</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nesi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saroglia</surname>
                    <given-names>EH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miniero</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martino</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tovo</surname>
                    <given-names>PA</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Successful unrelated cord blood transplantation in two children with severe combined immunodeficiency syndrome.</article-title>
                <source>Bone Marrow Transplant</source>
                <volume>31</volume>
                <fpage>133</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">12621496</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.fischer.2010.107">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fischer</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Picard</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chemin</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dogniaux</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>le Deist</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hivroz</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>ZAP70: a master regulator of adaptive immunity.</article-title>
                <source>Semin Immunopathol</source>
                <volume>32</volume>
                <fpage>107</fpage>
                <lpage>16</lpage>
                <pub-id pub-id-type="pmid">20135127</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.gavino.2017.1688">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gavino</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Landekic</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeng</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wu</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jung</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhong</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cohen-Blanchet</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Langelier</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neyret</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lejtenyi</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rochefort</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cotton-Montpetit</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCusker</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mazer</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Veillette</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vinh</surname>
                    <given-names>DC</given-names>
                  </name>
                </person-group>
                <year>2017</year>
                <article-title>Morpholino-based correction of hypomorphic ZAP70 mutation in an adult with combined immunodeficiency.</article-title>
                <source>J Allergy Clin Immunol.</source>
                <volume>139</volume>
                <fpage>1688</fpage>
                <lpage>92.e10</lpage>
                <pub-id pub-id-type="pmid">28216435</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.gelfand.1995.1057">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gelfand</surname>
                    <given-names>EW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weinberg</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mazer</surname>
                    <given-names>BD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kadlecek</surname>
                    <given-names>TA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weiss</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>1995</year>
                <article-title>Absence of ZAP-70 prevents signaling through the antigen receptor on peripheral blood T cells but not on thymocytes.</article-title>
                <source>J Exp Med</source>
                <volume>182</volume>
                <fpage>1057</fpage>
                <lpage>65</lpage>
                <pub-id pub-id-type="pmid">7561679</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.grazioli.2014.209">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Grazioli</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bennett</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hildebrand</surname>
                    <given-names>KJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vallance</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turvey</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Junker</surname>
                    <given-names>AK</given-names>
                  </name>
                </person-group>
                <year>2014</year>
                <article-title>Limitation of TREC-based newborn screening for ZAP70 Severe Combined Immunodeficiency.</article-title>
                <source>Clin Immunol</source>
                <volume>153</volume>
                <fpage>209</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">24797280</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.hauck.2015.103">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hauck</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blumenthal</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fuchs</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lenoir</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Speckmann</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vraetz</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mannhardt-Laakmann</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lambert</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gil</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Borte</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Audrain</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwarz</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lim</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schamel</surname>
                    <given-names>WW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fischer</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ehl</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rensing-Ehl</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Picard</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Latour</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2015</year>
                <article-title>SYK expression endows human ZAP70-deficient CD8 T cells with residual TCR signaling.</article-title>
                <source>Clin Immunol</source>
                <volume>161</volume>
                <fpage>103</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">26187144</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.h_nig.2012.305">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>H&#x000f6;nig</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schuetz</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwarz</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rojewski</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jacobsen</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lahr</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Debatin</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schulz</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Friedrich</surname>
                    <given-names>W</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Immunological reconstitution in a patient with ZAP-70 deficiency following transfusion of blood lymphocytes from a previously transplanted sibling without conditioning.</article-title>
                <source>Bone Marrow Transplant</source>
                <volume>47</volume>
                <fpage>305</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">21441961</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.irla.2008.e2059">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Irla</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saade</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kissenpfennig</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poulin</surname>
                    <given-names>LF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leserman</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marche</surname>
                    <given-names>PN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jouvin-Marche</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berger</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nguyen</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>ZAP-70 restoration in mice by in vivo thymic electroporation.</article-title>
                <source>PloS One</source>
                <volume>3</volume>
                <fpage>e2059</fpage>
                <pub-id pub-id-type="pmid">18446234</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.jilkina.2014.324">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jilkina</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thompson</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kwan</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Caeseele</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rockman-Greenberg</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schroeder</surname>
                    <given-names>ML</given-names>
                  </name>
                </person-group>
                <year>2014</year>
                <article-title>Retrospective TREC testing of newborns with Severe Combined Immunodeficiency and other primary immunodeficiency diseases.</article-title>
                <source>Mol Genet Metab Rep</source>
                <volume>1</volume>
                <fpage>324</fpage>
                <lpage>33</lpage>
                <pub-id pub-id-type="pmid">27896105</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.karaca.2013.189">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Karaca</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karakoc-Aydiner</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bayrak</surname>
                    <given-names>OF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keles</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sevli</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barlan</surname>
                    <given-names>IB</given-names>
                  </name>
                  <etal/>
                </person-group>
                <year>2013</year>
                <article-title>Identification of a novel mutation in ZAP70 and prenatal diagnosis in a Turkish family with severe combined immunodeficiency disorder.</article-title>
                <source>Gene</source>
                <volume>512</volume>
                <fpage>189</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">23124046</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.katamura.1999.124">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Katamura</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tai</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tachibana</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamabe</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohmori</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mayumi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yuksel</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chatila</surname>
                    <given-names>TA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ozen</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Existence of activated and memory CD4+ T cells in peripheral blood and their skin infiltration in CD8 deficiency.</article-title>
                <source>Clin Exp Immunol</source>
                <volume>115</volume>
                <fpage>124</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">9933431</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.kim.2013.1233">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>VH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murguia</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schechter</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grunebaum</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roifman</surname>
                    <given-names>CM</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Emergency treatment for zeta chain-associated protein of 70 kDa (ZAP70) deficiency.</article-title>
                <source>J Allergy Clin Immunol.</source>
                <volume>131</volume>
                <fpage>1233</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">23141738</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.kofler.2004.1416">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kofler</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buning</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mayr</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bund</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baumert</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hallek</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wendtner</surname>
                    <given-names>CM</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Engagement of the B-cell antigen receptor (BCR) allows efficient transduction of ZAP-70-positive primary B-CLL cells by recombinant adeno-associated virus (rAAV) vectors.</article-title>
                <source>Gene Ther</source>
                <volume>11</volume>
                <fpage>1416</fpage>
                <lpage>24</lpage>
                <pub-id pub-id-type="pmid">15269708</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.mancebo.2008.479">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mancebo</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moreno-Pelayo</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Menc&#x000ed;a</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de la Calle-Mart&#x000ed;n</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allende</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sivadorai</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kalaydjieva</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertranpetit</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coto</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Calleja-Antol&#x000ed;n</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruiz-Contreras</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paz-Artal</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Gly111Ser mutation in CD8A gene causing CD8 immunodeficiency is found in Spanish Gypsies.</article-title>
                <source>Mol Immunol</source>
                <volume>45</volume>
                <fpage>479</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">17658607</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.matsuda.1999.34515">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Matsuda</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki-Fujimoto</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minowa</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ueno</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Katamura</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koyasu</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Temperature-sensitive ZAP70 mutants degrading through a proteasome-independent pathway. Restoration of a kinase domain mutant by Cdc37.</article-title>
                <source>J Biol Chem</source>
                <volume>274</volume>
                <fpage>34515</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">10574909</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.meinl.2000.3578">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Meinl</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lengenfelder</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blank</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pirzer</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barata</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hivroz</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Differential requirement of ZAP-70 for CD2-mediated activation pathways of mature human T cells.</article-title>
                <source>J Immunol</source>
                <volume>165</volume>
                <fpage>3578</fpage>
                <lpage>83</lpage>
                <pub-id pub-id-type="pmid">11034358</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.newell.2011.517">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Newell</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dadi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldberg</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ngan</surname>
                    <given-names>BY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grunebaum</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roifman</surname>
                    <given-names>CM</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Diffuse large B-cell lymphoma as presenting feature of Zap-70 deficiency.</article-title>
                <source>J Allergy Clin Immunol.</source>
                <volume>127</volume>
                <fpage>517</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">21094993</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.noraz.2000.15832">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Noraz</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwarz</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steinberg</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dardalhon</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rebouissou</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hipskind</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Friedrich</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yssel</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bacon</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Alternative antigen receptor (TCR) signaling in T cells derived from ZAP-70-deficient patients expressing high levels of Syk.</article-title>
                <source>J Biol Chem</source>
                <volume>275</volume>
                <fpage>15832</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">10748099</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.pai.2014.434">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pai</surname>
                    <given-names>SY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Logan</surname>
                    <given-names>BR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Griffith</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buckley</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parrott</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dvorak</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kapoor</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanson</surname>
                    <given-names>IC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Filipovich</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jyonouchi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sullivan</surname>
                    <given-names>KE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Small</surname>
                    <given-names>TN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burroughs</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Skoda-Smith</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haight</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grizzle</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pulsipher</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chan</surname>
                    <given-names>KW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fuleihan</surname>
                    <given-names>RL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haddad</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loechelt</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aquino</surname>
                    <given-names>VM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gillio</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davis</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knutsen</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moore</surname>
                    <given-names>TB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schroeder</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldman</surname>
                    <given-names>FD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Connelly</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Porteus</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xiang</surname>
                    <given-names>Q</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shearer</surname>
                    <given-names>WT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fleisher</surname>
                    <given-names>TA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kohn</surname>
                    <given-names>DB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Puck</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Notarangelo</surname>
                    <given-names>LD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cowan</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Reilly</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>2014</year>
                <article-title>Transplantation outcomes for severe combined immunodeficiency, 2000-2009.</article-title>
                <source>N Engl J Med</source>
                <volume>371</volume>
                <fpage>434</fpage>
                <lpage>46</lpage>
                <pub-id pub-id-type="pmid">25075835</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.picard.2009.1966">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Picard</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dogniaux</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chemin</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maciorowski</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lim</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mazerolles</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rieux-Laucat</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stolzenberg</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Debre</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Magny</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Le Deist</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fischer</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hivroz</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Hypomorphic mutation of ZAP70 in human results in a late onset immunodeficiency and no autoimmunity.</article-title>
                <source>Eur J Immunol.</source>
                <year>2009</year>
                <volume>39</volume>
                <fpage>1966</fpage>
                <lpage>76</lpage>
                <pub-id pub-id-type="pmid">19548248</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.poliani.2013">
              <mixed-citation publication-type="other">Poliani PL, Fontana E, Roifman CM, Notarangelo LD (2013) Zeta chain-associated protein of 70 kDa (ZAP70) deficiency in human subjects is associated with abnormalities of thymic stromal cells: Implications for T-cell tolerance. J Allergy Clin Immunol. 131:597-600.e591-2.</mixed-citation>
            </ref>
            <ref id="zap70-scid.REF.roifman.2010.1226">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Roifman</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dadi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Somech</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nahum</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sharfe</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Characterization of zeta-associated protein, 70 kd (ZAP70)-deficient human lymphocytes.</article-title>
                <source>J Allergy Clin Immunol.</source>
                <volume>126</volume>
                <fpage>1226</fpage>
                <lpage>33.e1</lpage>
                <pub-id pub-id-type="pmid">20864151</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.roifman.2012.177">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Roifman</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Somech</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kavadas</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pires</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nahum</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dalal</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grunebaum</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Defining combined immunodeficiency.</article-title>
                <source>J Allergy Clin Immunol.</source>
                <volume>130</volume>
                <fpage>177</fpage>
                <lpage>83</lpage>
                <pub-id pub-id-type="pmid">22664165</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.santos.2010.530">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Santos</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dias</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cordeiro</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cordinha</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lemos</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rocha</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Faria</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Severe axillary lymphadenitis after BCG vaccination: alert for primary immunodeficiencies.</article-title>
                <source>J Microbiol Immunol Infect.</source>
                <volume>43</volume>
                <fpage>530</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">21195982</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.schroeder.2016.50">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schroeder</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Triggs-Raine</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zelinski</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2016</year>
                <article-title>Genotyping an immunodeficiency causing c.1624-11G&#x0003e;A ZAP70 mutation in Canadian Mennonites.</article-title>
                <source>BMC Med Genet</source>
                <volume>17</volume>
                <fpage>50</fpage>
                <pub-id pub-id-type="pmid">27448562</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.shirkani.2017.70">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shirkani</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shahrooei</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Azizi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rokni-Zadeh</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abolhassani</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Farrokhi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frans</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bossuyt</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aghamohammadi</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2017</year>
                <article-title>Novel mutation of ZAP-70-related combined immunodeficiency: first case from the National Iranian Registry and review of the literature.</article-title>
                <source>Immunol Invest</source>
                <volume>46</volume>
                <fpage>70</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">27759478</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.skodasmith.2001.329">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Skoda-Smith</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Douglas</surname>
                    <given-names>VK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mehta</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Graham-Pole</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wingard</surname>
                    <given-names>JR</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Treatment of post-transplant lymphoproliferative disease with induction chemotherapy followed by haploidentical peripheral blood stem cell transplantation and Rituximab.</article-title>
                <source>Bone Marrow Transplant</source>
                <volume>27</volume>
                <fpage>329</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">11277182</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.steinberg.2000.1392">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Steinberg</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Swainson</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwarz</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boyer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Friedrich</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yssel</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Noraz</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Retrovirus-mediated transduction of primary ZAP-70-deficient human T cells results in the selective growth advantage of gene-corrected cells: implications for gene therapy.</article-title>
                <source>Gene Ther</source>
                <volume>7</volume>
                <fpage>1392</fpage>
                <lpage>400</lpage>
                <pub-id pub-id-type="pmid">10981666</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.toyabe.2001.164">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Toyabe</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watanabe</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harada</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karasawa</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uchiyama</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Specific immunoglobulin E responses in ZAP-70-deficient patients are mediated by Syk-dependent T-cell receptor signalling.</article-title>
                <source>Immunology</source>
                <volume>103</volume>
                <fpage>164</fpage>
                <lpage>71</lpage>
                <pub-id pub-id-type="pmid">11412303</pub-id>
              </element-citation>
            </ref>
            <ref id="zap70-scid.REF.turul.2009.87">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Turul</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tezcan</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Artac</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Bruin-Versteeg</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barendregt</surname>
                    <given-names>BH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reisli</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanal</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Dongen</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Burg</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Clinical heterogeneity can hamper the diagnosis of patients with ZAP70 deficiency.</article-title>
                <source>Eur J Pediatr</source>
                <volume>168</volume>
                <fpage>87</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">18509675</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="zap70-scid.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="zap70-scid.Author_History">
          <title>Author History</title>
          <p>Tara Capece, MPH; University of Pittsburgh (2009-2012)Marc Ikeda, MD; Children&#x02019;s Hospital of Pittsburgh (2012-2014)Allyson Larkin, MD; Children&#x02019;s Hospital of Pittsburgh (2012-2017)David Nash, MD; Children&#x02019;s Hospital of Pittsburgh (2009-2012)Stacy Lyn Rosenberg, MD; Children&#x02019;s Hospital of Pittsburgh (2014-2017)Mark Vander Lugt, MD (2017-present)Kelly Walkovich, MD (2017-present)</p>
        </sec>
        <sec id="zap70-scid.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>8 June 2017 (sw) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>25 September 2014 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>6 September 2012 (cd) Revision: prenatal diagnosis available clinically</p>
            </list-item>
            <list-item>
              <p>1 March 2012 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>20 October 2009 (me) Review posted live</p>
            </list-item>
            <list-item>
              <p>1 June 2009 (tc) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
